Law360, New York (March 11, 2013, 1:55 PM EDT) -- Mylan Inc. on Friday asked a New York federal judge to toss a patent infringement suit over Teva Pharmaceutical Industries Ltd.’s Copaxone, saying it was permitted under a federal safe harbor to use proprietary processes when developing a generic version of the multiple sclerosis drug.
In its motion to dismiss, Mylan cited a provision of federal law that allows use of patented data if the purpose is solely to create a generic drug.
“Any alleged use of the patented markers in connection with the preparation of the...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.